- Home
- ZNTL vs VNDA Comparison
ZNTL vs VNDA Comparison
Compare ZNTL & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZNTL | VNDA |
|---|---|---|
| Founded | 2014 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 289.0M | 361.4M |
| IPO Year | 2020 | 2005 |
Fundamental Metrics
Financial Performance| Metric | ZNTL | VNDA |
|---|---|---|
| Price | $3.09 | $5.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $6.60 | ★ $14.90 |
| AVG Volume (30 Days) | ★ 799.0K | 635.3K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.03 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $216,105,000.00 |
| Revenue This Year | N/A | $21.35 |
| Revenue Next Year | N/A | $37.40 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 8.72 |
| 52 Week Low | $1.21 | $4.27 |
| 52 Week High | $6.95 | $9.91 |
Technical Indicators
Market Signals| Indicator | ZNTL | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 30.92 | 42.97 |
| Support Level | $2.09 | $4.94 |
| Resistance Level | $3.30 | $5.55 |
| Average True Range (ATR) | 0.22 | 0.18 |
| MACD | -0.06 | -0.03 |
| Stochastic Oscillator | 13.39 | 17.14 |
Price Performance
Historical ComparisonAbout ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.